A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Summary

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

Timeline

Start

2022-01-30

Primary completion

2025-03-17

Completion

2025-03-17

Outcome

Outcome not reported

Stopped (Business): “The sponsor has decided to adjust the development strategy of the investigational drug in this study.”

Drugs

Indications